BioSpace News Archive

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that Emil D. Kakkis, M.D., Ph.D., the company’s chief executive officer and president, will participate in a panel discussion at Citi’s 18th Annual BioPharma Conference on Wednesday, September 6, 2023, at 8:50 a.m. EST and a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference on Tuesday, September 12, 2023, at 8:50 a.m. EST.

Boston Immune Technologies and Therapeutics, Inc. (BITT), a clinical-stage biotechnology company developing novel tumor necrosis factor superfamily receptor (TNFSR) antagonist antibodies, announced today the award of funding from the National Institutes of Health (NIH) to support the preclinical development of BITT’s CD40 antagonist antibody.

Today, Hinge Health, the industry leader for helping people move beyond pain, announced results from a new medical and pharmacy claims study illustrating how the company’s complete approach to care, combining digital exercise therapy (ET) with a clinical care team of physical therapists and health coaches, lowers the odds that individuals in pain will start - or continue - taking opioids.

BriaCell Therapeutics Corp. announces that the Company has closed the previously announced plan of arrangement spinout transaction pursuant to which certain pipeline assets of the Company, including Bria-TILsRx™ and protein kinase C delta inhibitors for multiple indications including cancer, were spun-out to BriaPro Therapeutics Corp., resulting in a 2/3rd owned subsidiary of the Company with the remaining 1/3rd held by BriaCell shareholders.

The global AI in medical imaging market is estimated grow from USD 762.84 million in 2022 to reach around USD 14,423.15 million by 2032, growing at a healthy CAGR of 34.8% from 2023 to 2032.

Praxis Precision Medicines, Inc. announced that it will present data from two of its clinical-stage epilepsy programs at the upcoming 35th International Epilepsy Congress, to be held on September 2-6, 2023 in Dublin, Ireland.

Arcutis Biotherapeutics, Inc. announced the publication of its annual Environmental, Social, and Governance report.

Peak Bio, Inc., is a clinical-stage biopharmaceutical company focused on developing the next-generation of therapeutics to treat oncology and inflammatory orphan/rare diseases.

BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced it will host a virtual KOL event titled NE3107―Putting Data in Context, ahead of the upcoming Phase 3 results in Alzheimer’s Disease.

Halia Therapeutics, a clinical-stage biopharmaceutical company advancing innovative medicines to treat a broad range of diseases driven by chronic inflammation and neurodegeneration, today announced they will be presenting new data at the 17th Annual PAINWeek Conference on Thursday, September 7, at 5:30 p.m. PDT/8:30 p.m. EDT.